Primary source: Ministry of Food and Drug Safety (MFDS)
MFDS has issued revised guidelines and checklists for new drug applications, specifically addressing the review of safety data and RMPs as part of the marketing authorization process.
These changes aim to streamline the drug licensing process, reducing potential regulatory delays by clarifying expectations around safety monitoring and risk mitigation for marketing authorization holders (MAHs).
Marketing authorization holders (MAHs) must align their RMP submissions with the updated MFDS checklists to comply with the new review procedures.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Revised steps for preliminary review of drug development stages. Enhanced focus on consistent application of safety standards during the pre-IND and pre-CTA phases to expedite clinical trial approvals.
Clinical trial sponsors must review the revised procedures to ensure their preliminary safety assessments and monitoring plans meet the updated MFDS standards. The 6th revision affects the submission timing and format for safety reviews in the early stages of development, impacting clinical trial safety reporting (GCP) strategies.
Marketing authorization holders (MAHs) must align their RMP submissions with the updated MFDS checklists to comply with the new review procedures.
The Ministry of Food and Drug Safety (MFDS) of South Korea has revised its work procedures for the licensing and review of new drug applications. The guidelines include updated checklists that focus on safety data and Risk Management Plans (RMPs), clarifying the review process and expectations to ensure compliance with current South Korean safety standards.
What changed: MFDS has issued revised guidelines and checklists for new drug applications, specifically addressing the review of safety data and RMPs as part of the marketing authorization process.
Why it matters: These changes aim to streamline the drug licensing process, reducing potential regulatory delays by clarifying expectations around safety monitoring and risk mitigation for marketing authorization holders (MAHs).
Practical implication: Marketing authorization holders (MAHs) must align their RMP submissions with the updated MFDS checklists to comply with the new review procedures.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
